Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . WEGO 威 高 山東 威 高 集團 醫用 高分子 製品 股份有限公司 Shandong Weigao Group Medical Polymer Company Limited * ( a joint stock limited company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 1066 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 SUMMARY For the six months ended 30 June 2021 ( the “ Period ” ) , the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited ( the “ Company ” ) and its subsidiaries ( the “ Group ” ) was approximately RMB6,229,604,000 , representing an increase of approximately 19.4 % over approximately RMB5,215,509,000 as restated for the same period last year . The restated represents the acquisition of Wego Healthcare Fund Holding Corporation by the Company from its immediate holding company , Weigao Holding Company Limited during the Period . Under the relevant accounting standards , it is as if the merger of common control had taken place from the date when the Company's immediate holding company , Weigao Holding Company Limited , had control of Wego Healthcare Fund Holding Corporation as the Company and Wego Healthcare Fund Holding Corporation are jointly controlled by Weihai Weigao International Medical Investment Holding Company Limited before and after the Acquisition . The unaudited net profit attributable to the shareholders of the Group for the six months ended 30 June 2021 was approximately RMB1,209,394,000 , representing an increase of approximately 21.4 % over approximately RMB995,841,000 as restated for the same period last year . The board of directors ( the " Board " ) proposed the distribution of an interim dividend for the six months ended 30 June 2021 of RMB0.077 per share ( same period in 2020 : RMB0.062 per share ) . The proposal is subject to the approval of shareholders of the Company ( " Shareholders " ) at the forthcoming extraordinary general meeting . * For identification purpose only 1